Cancer immunotherapy has recently drawn much attention for its potentiality on clinic. However, the problem of side effects induced by poor selectivity and high doses still exists. In this review, Lulu Cai et al. briefly summarize progress in the application of engineered biomaterials to the localized delivery of cancer immunotherapy.

Fig. 1 Schematic of engineered biomaterials for localized delivery of cancer immunotherapeutics.

 

 

 

Article Access: https://onlinelibrary.wiley.com/doi/10.1002/mco2.8

 

 

                                                                           

Website for MedComm: https://onlinelibrary.wiley.com/journal/26882663

Looking forward to your contributions.